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Abstract
Intra bone marrow-bone marrow transplantation (IBM- BMT) + thymus transplantation (TT)
has been shown to reduce the incidence of graft versus host disease (GVHD) and restore
donor-derived T cell function. In addition, an increase in insulin sensitivity occurred in db/db
mice after IBM-BMT+TT treatment. Heme oxygenase (HO)-1 is a stress inducible enzyme
which exert antioxidant, antiapoptotic, and immune-modulating properties. We examined
whether IBM-BMT+TT could modulate the expression of HO-1 in the kidneys of db/db mice.
Six-week-old db/db mice with blood glucose levels higher than 250 mg/dl were treated with
IBM-BMT+TT. Six weeks later, the db/db mice showed decreased body weight, blood glucose
levels and insulin, and increased plasma adiponectin levels. The upregulation of HO-1 was
associated with significantly (p<0.05) increased levels of peNOS and pAKT, but decreased
levels of iNOS in the kidneys of db/db mice. Plasma creatinine levels also decreased (p<0.05),
and the expression of type IV collagen was improved. Thus IBM-BMT+TT unregulated the
expression of HO-1, peNOS and pAKT, while decreasing iNOS levels in the kidney of db/db
mice. This was associated with an improvement in renal function.
Key words: IBM-BMT+TT, antioxidant, HO-1, diabetic nephropathy.

Introduction
Heme oxygenase (HO)-1 is a stress inducible
enzyme that catalyzes the degradation of heme proteins into free iron, CO and biliverdin, which is then
rapidly converted into bilirubin. These catabolic end
products exert antioxidant, antiapoptotic, and immune-modulating properties, rendering the overall
function of HO-1 to be cytoprotective [1, 2]. Graft
versus host disease (GVHD) is a major side effect of
allogenic bone marrow transplantation (BMT) [3].
Intra bone marrow- BMT (IBM-BMT) appears to offer
the best approach for allogenic BMT, as manifested by
a reduced incidence of GVHD and the restoration of
donor-derived T cell function [4-6]. We recently re-

ported that, in db/db mice treated with IBM-BMT+
thymus (TT) transplantation, CD4/CD8 ratios were
normalized with a consequent increase in plasma
adiponectin levels and insulin sensitivity. In addition,
the expression of pancreatic phosphorylated AK
transforming factor (pAKT), phosphorylated liver
kinase B1 (pLKB1), phosphorylated adenosine
monophosphate-activated protein kinase (pAMPK)
and HO-1 increased in thus-treated db/db mice [7].
The db/db mouse presents with renal abnormalities including proteinuria, glomerular hypertrophy, and glomerulosclerosis [8, 9], thereby making it
an ideal animal model in which to study renal and
http://www.biolsci.org
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vascular dysfunction in diabetic nephropathy (DN).
DN is the major cause of end-stage renal failure,
mainly due to the increased incidence of type 2 diabetes mellitus [10]. Oxidative stress (OS) is considered
a significant pathogenic factor in the development of
diabetic vascular complications, including nephropathy [11, 12]. The beneficial effect of increased HO-1
expression and HO activity further suggests that the
abnormality in endothelial progenitor cells is due to a
mesenchymal stem cell (MSC) disorder exacerbated
by OS and decreased levels of adiponectin [13].
In the present study, we examined whether allogenic IBM-BMT+TT modulated the expression of
HO-1 in the kidneys of db/db mice and show that this
intervention does indeed upregulate the expression of
HO-1, phosphorylated endothelial nitric oxide synthase (peNOS) and pAKT, decrease inducible NOS
(iNOS), and improve renal function, therefore
providing a mechanistic basis for the therapeutic use
of IBM-BMT+TT.

Materials and methods
Animals
Six-, 12- and 30-wk-old BKS.Cg-m+Leprdb/
+Leprdb/J (H-2Kd) (db/db) mice and age-matched
lean mice were purchased from Charles River Laboratories (Yokohama, Japan) and maintained in animal
facilities under specific pathogen-free conditions. All
procedures were performed under protocols approved by the Institutional Animal Care and Use
Committee at Kansai Medical University. Body
weight and blood glucose levels were measured each
week. Blood glucose levels higher than 250 mg/dl on
two consecutive measurements were considered to
indicate the onset of diabetes. Each experiment was
repeated three times.

IBM-BMT+TT
Six-wk-old db/db mice with blood glucose levels greater than 250 mg/dl and proteinuria greater
than ++ on two consecutive measurements received
fractionated irradiation twice a day (5.0 Gy×2, 4-hour
interval). One day after irradiation, whole BMCs from
B6 mice were injected into the recipient mice
(1×107/mouse) by IBM-BMT using our previously-described method [7]. Simultaneously, the thymus
from newborn B6 mice was grafted under the renal
capsule of the left kidney of the recipient mice. All
treated mice were sacrificed 6 wks after IBM-BMT+TT
treatment.
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Immunochemistry and measurement of nitric
oxide (NO) levels
The pancreata, livers, kidneys and bones of lean
and db mice were removed at each time point. After
the tissues were fixed in 10% formalin for 24 hours at
room temperature, they were embedded in paraffin.
The sections (3-µm thick) were stained with hematoxylin and eosin. The pancreata were stained with
polyclonal guinea pig anti-swine insulin antibody
(N1542, Dako Cytomation, CA). The kidneys were
stained with collagen type IV (Sigma-Aldrich, MO),
pAKT, iNOS and eNOS (Abcam PLC, Cambridge,
UK) antibodies. The stained sections were examined
under a microscope.
NO levels in the kidneys were measured according to the manufacturer’s protocol using a Nitric
Oxide Assay Kit (BioAssay Systems, Hayward, CA).

Electron microscopy
The fixed renal cortices were embedded in epoxy
resin using conventional methods [14]. Kidney tissue
was fixed in 2.5% glutaraldehyde in 0.1M PBS, pH 7.4.
Samples were washed and post fixed with 2% aqueous OsO4. The samples were then dehydrated with
serially-increasing concentrations of ethanol (60 to
100%), and were infiltrated with epon mixed with
methyl nadic anhydride (TAAB Laboratories, UK),
Dodecenyl succinic anhydride (TAAB Laboratories),
and Quetol-812 and DMP-30 (Nishin Company, Japan). Ultrathin sections were prepared, stained using
uranyl acetate and lead citrate, and then examined
with a JEM-1400A electron microscope (JEOL, Tokyo,
Japan). The measurements were taken from electron
micrographs with magnifications of x2,500 and
x12,000.

Adiponectin, insulin, creatinine and pancreatic
insulin content measurements
Adiponectin was determined in mouse plasma
using an ELISA assay (R&D Systems, Inc. MN and
Invitrogen Corporation CA). Insulin was measured
using an ELISA kit (Morinaga, Yokohama, Japan).
Plasma creatinine was measured according to
the manufacturer’s protocols using a plasma creatinine detection kit (Arbor Assays, Michigan).
For insulin content measurement, the pancreas
was isolated and weighed, and then placed in 3ml
cold acid ethanol (0.18M HCl in 70% ethanol) and
homogenated. This was kept overnight at 4°C and
centrifuged at 2400rpm for 30min at 4°C. The supernatant was transferred and stored at -20°C for measurement using ELISA.

http://www.biolsci.org
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Western blot analysis of kidney HO-1, peNOS,
AKT, pAKT, and iNOS
At sacrifice, kidneys were dissected, then pooled
for each mouse in order to measure signaling molecules. Specimens were stored at -140°C until assayed.
Frozen kidney tissues were pulverized under liquid
nitrogen and placed in a homogenization buffer
(mmol/l: 10 phosphate buffer, 250 sucrose, 1 EDTA,
0.1 PMSF and 0.1% v/v tergitol, pH 7.5). Homogenates were centrifuged at 27,000 g for 10 min at 4ºC,
and the supernatant was then isolated and protein
levels were obtained by immunoblotting with the
relevant antibodies. Antibodies against HO-1, AKT,
phosphorylated AKT (pAKT), eNOS, peNOS and
iNOS were obtained from Cell Signaling Technology,
Inc. (Beverly, MA). Antibodies were prepared by dilution as described previously [15, 16].

Flow cytometric analyses
Peripheral blood mononuclear cells were obtained from the tail vein of mice 30 days after transplantation. These cells were stained with antibodies
against PE-H-2Kd, PE-CD4, PE-CD8a and FITC-H-2Kb
(BD Bioscience Pharmingen, San Diego, CA) for 30
min on ice. After washing twice with 2% FCS / PBS
and lysing red blood cells, the 10000 events acquired
were analyzed by FACScan (BD Bioscience). Isotype-matched immunoglobulins were used as controls.

Statistical analysis
Statistical significance between experimental
groups was determined by the Fisher method of
analysis of multiple comparisons. For comparison
between treatment groups, the null hypothesis was
tested by either a single-factor ANOVA for multiple
groups or unpaired t test for two groups. Statistical
significance was regarded as significant at p<0.05.

Results
Body weight, thymus weight, and morphology
of pancreas and bone, and insulin content of
pancreas islet
We first confirmed the parameters (body weight,
thymus weight and morphology of pancreas and bone
marrow) of the db/db mice and lean mice (as control)
maintained in our animal facilities (Fig.1), since food
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and environment may affect some parameters of
db/db mice. As seen in Fig. 1A, the body weight of
12-wk-old lean mice was significantly higher than that
of 6-wk-old lean mice (30.4 ±0.5 vs 22.6±0.1 g, p<
0.001). Similar results occurred in the db/db mice
(53.2 ±1.7 vs 33.5±0.03 g, p< 0.001). However, although the body weight of 30-wk-old db/db mice was
significantly higher than that of 12-wk-old db/db
mice (61.2±0.6 vs 53.2± 1.7 g, p< 0.01), there was no
significant difference in body weight between
30-wk-old and 12-wk-old lean mice (32.4±0.5 vs 30.4±
0.5 g). As shown in Fig. 1B, thymus weight was significantly lower in the 6-wk-, 12-wk and 30-wk-old
db/db mice than in the age-matched lean mice (51.7
±4.7 vs 75.7±3.3, 21.3 ±0.9 vs 49±4.0, 20.5 ±1.2 vs
43±4.1mg, p < 0.05 at each time point).
On HE staining, 12-wk- and 30-wk-old db/db
mice (Fig. 1E and F) exhibited larger islets than 6
wk-old db/db mice and lean mice (Fig. 1C and D).
More adipocytes were present in the bone marrow of
12-wk- and 30-wk-old db/db mice (Fig. 1H-J) than in
lean mice (Fig. 1G).
The db/db mouse shows insulin resistance and
insulin-positive cell failure. The insulin content
(brown color) was much lower in the larger islets of
6-wk-, 12-wk- and 30-wk-old db/db mice (Fig. 1L-N)
than in those of lean mice (Fig. 1K), suggesting that
more insulin was secreted into the peripheral blood in
the db/db mice. Pancreatic insulin contents of lean
mice (2336±84.5 pg/ml per mg pancreas), and 6-wk(1149±37.5 pg/ml per pancreas), 12-wk- (521±21.7
pg/ml per mg pancreas), and 30-wk- (180±21.3 pg/ml
per mg pancreas) old db/db mice were measured by
ELISA.

Plasma creatinine levels and histology of the
kidneys of db/db mice
As shown in Fig. 1O, plasma creatinine levels
were significantly higher in 12-wk-old when compared to 6-wk-old db/db mice (3.41±0.20 vs 1.47±0.46
mg/dl, p<0.05), and in 30-wk-old compared to
12-wk-old db/db mice (4.65±0.03 vs 3.41±0.20 mg/dl,
p<0.05). Electron microscopic images of the kidneys
are shown in Fig. 1P-S. 12-wk and 30-wk db/db mice
exhibited severe podocyte foot fusion. Electron dense
deposits and increased numbers of mesangium cells
were observed in the 30-wk-old db/db mice (Fig. 1R
and S).

http://www.biolsci.org
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Figure 1. Body weight, thymus weight and the morphology of pancreas and bone marrow, and expression of insulin on
the pancreata, and plasma creatinine levels and images of electron microcopy. (A) Body weights are shown (*p< 0.01). (B)
Thymus weights are shown (*p<0.05). (C-J) HE staining of pancreas and bone marrow of the lean and db/db mice at each age. The islets
are shown (* in Fig.C-F). The adipocytes are shown in db/db mice (arrows in Fig. H-J). (K-N) Immunochemistry staining for insulin (arrows)
was performed. Scale bar =50μm in Fig. C-J, Scale bar =25μm in Fig. K-N. (O) Plasma creatinine levels of lean, (p< 0.05). (P-S) EM of
kidneys. Podocyte foot fusion is shown in Fig. 3Q and R (arrows). Electron dense deposits and increased mesangium cells (*) are shown
in Fig. 1R and S. Scale bar =2μm in Fig. P-R, Scale bar =10μm in Fig. S. The results are mean±SE, n=6 in each group.

http://www.biolsci.org
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Improved body weight, blood glucose and
plasma adiponectin, and insulin levels 6 weeks
after treatment with IBM-BMT +TT

IBM-BMT+TT treatment resulted in a decrease
(p<0.05) in plasma insulin levels to the levels found in
age-matched lean animals (Fig. 2D).

As seen in Fig.2A, body weight was significantly
(p<0.01) lower in the IBM-BMT+TT treated db/db
mice than in the age-matched non-treated db/db
mice. In addition, fasting blood glucose levels (Fig.
2B) were significantly (p<0.01) lower in the treated
db/db mice than in the non-treated db/db mice. Indeed IBM-BMT+TT reduced blood glucose to the levels found in age-matched lean mice. As shown in Fig.
2C, the non-treated db/db mice exhibited a significantly (p<0.05) lower level of plasma adiponectin than
age-matched lean mice. However, the plasma adiponectin levels were significantly (p<0.05) increased
in the treated db/db mice when compared to the
non-treated db/db mice (Fig. 2C). Plasma insulin levels were higher (p<0.05) in the non-treated db/db
mice than in the age matched lean mice.

Lymphocyte subpopulations in peripheral
blood and cell number of thymus 6 weeks after
treatment with IBM-BMT +TT
The relative percentage of the total cell number
in the thymus was significantly (p<0.05) lower in the
non-treated db/db mice than in the lean mice (65.13%
of that of lean mice). The total cell number of the
thymus was significantly higher (p<0.05) increased in
the treated mice (97.9% of lean mice) (Fig. 3A). Figure
3B shows the percentages of donor-derived cells
(H-2Kb) in the peripheral blood of the treated db/db
mice. The percentages of donor-derived CD4+ and
CD8+ were 10.16% and 7.81% respectively, Figure 3C
and D.

Figure 2. Body weight, blood glucose levels, plasma adiponectin, insulin. (A) Body weights are shown. (B) Blood glucose levels
are shown. (C) Plasma adiponectin. (D) Plasma insulin.

http://www.biolsci.org

Int. J. Biol. Sci. 2012, 8

1340

Figure 3. Cell number of thymus and lymphocyte subpopulations in peripheral blood. (A) The relative percentage of total cell
numbers in the thymus, which was significantly increased in the db/db mice treated with IBM-BMT+TT. (B-D) Donor-derived cells in
peripheral blood, CD4+ cells and CD8+ cells are shown. The results are mean±SE, n=6 in each group.

Lymphocyte function
Approximately 98% of hematolymphoid cells
were of donor-origin in the peripheral blood of the
recipients one month after IBM-BMT+TT treatment.
Spleen cells of the recipient animals demonstrated
mitogen responses to lipopolysaccharide, in contrast
to those of non-treated db/db mice: 26296±2780.93 vs
19292±1310.42, respectively, p<0.05. In lean mice the
mitogen response was 31406±2780.93. These findings
suggest that IBM-BMT+TT treatment restores lymphocyte function in the db/db mice.

Expression of HO-1, iNOS, peNOS and pAKT
in the kidney of db/db mice treated with
IBM-BMT+TT
The expression of renal HO-1 was significantly
lower (p<0.05) in the non-treated db/db mice when
compared to lean mice, but significantly increased
(p<0.05) in db/db mice treated with IBM-BMT+TT,
when compared with non-treated db/db mice (Fig.

4A and B). The expression of iNOS was the receptacle
of HO-1 expression and was significantly (p<0.05)
higher in the non-treated db/db mice than in the lean
mice. Densitometry analyses revealed a significant
decrease in iNOS (p<0.05) in the kidney of treated
db/db mice when compared with non-treated db/db
mice (Fig. 4A and C).
The expression of pAKT and peNOS in the kidney was significantly lower (p<0.05) in the
non-treated db/db mice when compared to the lean
mice, but there was a significant increase in the expression of both pAKT and peNOS in the
IBM-BMT+TT treated db/db mice, when compared
with non-treated db/db mice (Fig. 4D-G, p<0.05). The
expression of type IV collagen (brown color) was
greater in the kidney of the non-treated db/db mice
(Fig. 4I) than in the lean mice (Fig. 4H). However, it
was significantly lower in the kidney (arrows in Fig.
4J) in the treated db/db mice than in the non-treated
db/db mice.

http://www.biolsci.org
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Figure 4. Expression of HO-1, iNOS AKT, pAKT, eNOS and peNOS in the kidney, and expression of type IV collagen in
the kidneys. (A-C) Western blot and densitometry analysis of HO-1, iNOS and actin proteins in kidneys of lean, non-treated db/db mice
and treated db/db mice. (D and E) Western blot and densitometry analyses of AKT and pAKT and actin proteins in kidney of lean,
non-treated db/db mice and treated db/db mice are shown. (F and G) Western blot and densitometry analyses of eNOS and peNOS and
actin proteins in kidney of lean, non-treated db/db mice and treated db/db mice are shown. Representative immunoblots are shown. There
were significant differences between non-treated and treated groups (p<0.05). (H-J) Immunochemistry staining for type IV collagen (*).
(K-S) Immunochemistry staining for eNOS, pAKT and iNOS. Scale bar =25µm. (T) NO levels in the kidney.

http://www.biolsci.org
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The expression of peNOS, pAKT and iNOS was
confirmed by immunochemistry staining (Fig. 4K-T).
eNOS positive cells were identified in the kidneys of
lean, non-treated and treated db/db mice ( arrow in
Fig. 4K-M). pAKT positive cells were identified in the
kidney of lean and treated db/db mice (arrow in Fig.
4N and P). However, none were found in the
non-treated db/db mice. iNOS positive cells were
identified in the kidney of non-treated db/db mice
(arrow and *in Fig. 4R).
As shown in Fig. 4T, NO levels in the kidney
were significantly lower in non-treated db/db mice
when compared to lean mice (0.35±0.004 vs 0.03±0.002
µM/mg, p<0.01). However, the NO levels were significantly higher in the kidney (0.09±0.005 vs
0.03±0.002 µM/mg, p<0.01) in the treated db/db mice
than in the non-treated db/db mice.

Discussion
Leptin receptor-deficient db/db mice exhibit
severe hereditary obesity [17] and display hormonal
imbalances and hematolymphoid defects [18, 19].
db/db mice exhibit a marked reduction in the size
and cellularity of the thymus [20, 21]. Thus we firstly
confirmed the body weight and thymus weight of
db/db and lean mice at each age that were maintained in our animal facilities. Meantime, the morphology of the pancreas, kidney and bone marrow
was also confirmed (Figure 1- 3). There were significant differences in body weight and thymus weight
between 6-wk-and 12-wk-old mice. The pancreas,
kidney and bone marrow showed differences in
morphology at each time point. Previous studies have
shown that IBM-BMT+TT improved insulin sensitivity in db/db mice 7 wks after treatment [7]. However,
there are no reports indicating whether IBM-BMT+TT
increased HO-1 expression, or benefited the kidney in
db/db mice, although a protective effect of BMT on
renal pathology has been reported [22].
HO-1 is the inducible form of HO (HO-2 is the
constitute form) and is increased in response to OS.
Increased levels of HO-1 slow the rate of weight gain
and decrease levels of TNF-α and IL-6, but increase
serum levels of adiponectin in obese diabetic mice
[15]. db/db mice treated with IBM-BMT+TT exhibited
a larger decrease in body weight and plasma insulin
levels than age-matched non-treated db/db mice.
Insulin administration to treated db/db mice produced a rapid decrease in blood glucose levels, suggesting
improved
insulin
sensitivity
after
IBM-BMT+TT treatment. In the present study, HO-1
expression increased in the kidney after IBM-BMT+TT
and was accompanied by an enhanced expression of
peNOS and pAKT. A reduction in the production of
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nitric oxide [23] and a decrease in the expression of
eNOS are reportedly associated with advanced DN
[24]. An increase in AKT signaling is considered an
important metabolic response to OS through the attenuation of ROS-mediated endothelial dysfunction
[25]. The up regulation of renal HO-1 expression with
a resultant increase in signaling molecules, including
adiponectin via the pAKT-pAMPK-peNOS pathway,
prevents the development of metabolic syndrome and
improves both vascular and renal function [26].
HO has been shown to be important for attenuating the overall production of reactive oxygen species (ROS) through its ability to degrade heme and to
produce carbon monoxide (CO), biliverdin/bilirubin,
and the release of free iron, which possess potent antioxidant properties and antiapoptotic effects [26].
Recently, the induction of HO-1 has been found to
reduce diabetic induced-glomerular injury and
apoptosis, and these effects are associated with decreased NF-κB-induced inflammation and oxidative
stress [27]. MSCs have the capacity to repair renal
injury, accelerate tubular proliferation and improve
renal function, and upregulate HO-1 expression and
increase HO activity, all are essential for MSC growth
and differentiation to the osteoblast lineage, which is
consistent with the role of HO-1 in hematopoietic
stem cell differentiation [28]. Induction of HO-1 by
cobalt-protoporphyrin IX in recipient mice before
conditioning and bone marrow transplantation (BMT)
results in a reduction of GVHD and improved survival [29]. One report has indicated that HO-1 in
dendritic cells may function as an inhibitor of the alloimmune response mediated by CD4+ T cells. HO-1
could thus play a key role in the design of therapies to
prolong allograft function, based on the potent alloimmunity modulating capacity of this enzyme [30].
Plasma adiponectin levels are also significantly
higher in treated db/db mice than in non-treated
db/db mice. Adiponectin is a key regulator of albuminuria, suppressing not only i) OS and albuminuria
but also ii) high levels of adiponectin phosphorylase
and iii) active AMPK, presumably via adipoR1, which
prevents OS and the fusion of the podocyte foot processes [31]. There is a report supporting the hypothesis that adiponectin is critical for both endothelial cell
survival and function via the activation of eNOS and
crosstalk between pAKT and pAMPK [32].
Bone marrow cells have the capacity to differentiate into mesangial cells [33, 34] and to transdifferentiate into podocytes. This is accompanied by the
re-expression of the defective collagen chains and
improved renal histology and function [35]. MSCs
have the capacity to repair renal injury, accelerate
tubular proliferation and improve renal function [36,
http://www.biolsci.org
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37]. Nephrons are of mesenchymal origin and stroma
cells are of crucial importance for signaling, leading to
the differentiation of both nephrons and collecting
ducts [38]. Bone marrow-derived mesangial cell progenitors may play a crucial role in the development
and progression of extracellular matrix accumulation
and mesangial cell proliferation in the db/db mouse.
Future studies to clarify extra-cellular matrix accumulation will focus on the donor-derived BM cells in
the kidneys of the recipient.
Type IV collagen is a major structural component of all basement membranes, including the glomerular basement membrane of the kidney in vertebrates and invertebrates [39, 40]. Our results show
that the expression of type IV collagen in the glomerulus was attenuated after IBM-BMT+TT. BM-derived
cells fuse with existing glomerular cells and thereby
provide therapeutic benefit or, alternatively, transfer
their nuclei to damaged podocytes and thereby enable
repair. Bone marrow-derived stem cells repair basement membrane collagen defects and reverse genetic
kidney disease [35].
Age-related hematologic changes are associated
with a decline in BM cellularity and a decline in
adaptive immunity [41, 42]. The thymus involutes
steadily with increasing age, resulting in a decreased
release of new naïve T cells to the periphery, thereby
affecting adaptive immunity [43]. The thymus also
undergoes age-related progressive involution with
decreased thymic lymphopoiesis, reduced thymic size
and disrupted thymic architecture. Our previous
studies demonstrated that the thymus is significantly
lighter in db/db mice than in age-matched lean mice.
When thymi from newborn C57BL6 mice were transplanted into db/db mice, the percentage of double-positive, double-negative and CD4+ cells in the
thymus was normalized, as was the CD4/CD8 ratio in
the peripheral blood [7], and the total cell number of
the thymus, suggesting that IBM-BMT+TT is capable
of restoring the immune repertoire and overcoming
the autoimmune response, which is considered to be
partly responsible for the development of diabetes.
IBM-BMT appears to be the most appropriate
strategy for allogenic BMT [4]. Moreover, allogenic
IBM-BMT+TT normalizes T cell subsets, cytokine
imbalance and insulin sensitivity in db/db mice [7].
Allogenic IBM-BMT+TT upregulates the expression of
HO-1 in kidney. This is followed by the upregulation
of peNOS and pAKT and a reduction in iNOS levels,
resulting in an improvement in renal function. This
therapeutic approach offers decided advantages in the
treatment of both autoimmune and hematological
diseases.
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